|  |
| --- |
| CNS Case Scenario – Meningioma  |
| Primary Site | C70.0 | Clinical Grade | 1 | Clinical Tumor Size | 120 |
| Laterality | 1 | Pathological Grade | 9 | Pathological Tumor Size | 999 |
| Histology | 9530 | Post Therapy Grade | - | Tumor Size Summary | 120 |
| Behavior | 0 |  |
| Stage Data items |
| AJCC Stage |
| Clinical T | 88 | Pathological T | 88 | Post-therapy T | - |
| cT Suffix | - | pT Suffix | - | ypT Suffix | - |
| Clinical N | 88 | Pathological N | 88 | Post-therapy N | - |
| cN Suffix | - | pN Suffix |  | ypN Suffix | - |
| Clinical M | 88 | Pathological M | 88 | Post-therapy M | - |
| Clinical Stage  | 88 | Pathological Stage | 88 | Post-therapy Stage | - |
| SS2018/EOD |
| Summary Stage 2018  | 8 |
| EOD Primary Tumor | 050 | EOD Regional Nodes | 888 | EOD Mets | 00 |
| Regional Nodes Positive | 99 | Regional Nodes Examined | 99 |  |
|  |
| SSDI |
| Brain Molecular Markers | 86 |  |
| Chromosome 1p Status | 6 |
| Chromosome 19q Status | 6 |
| MGMT | 6 |
|  |
| Treatment |
| Surgery Codes |  | **Systemic Therapy Codes** |
| Diagnostic Staging Procedure | 00 | Chemotherapy | 00 |
| Surgical Procedure of Primary Site | 0 | Hormone Therapy | 00 |
| Scope of Regional Lymph Node Surgery | 9 | Immunotherapy | 00 |
| Date of Regional LN Dissection/Flag | 11 |  |  |
| Surgical Procedure/ Other Site | 0 |  |  |

|  |
| --- |
| CNS Case Scenario – Oligodendroglioma  |
| Primary Site | C71.1 | Clinical Grade | 9 | Clinical Tumor Size | 510 |
| Laterality | 2 | Pathological Grade | 3 | Pathological Tumor Size | 999 |
| Histology | 9451 | Post Therapy Grade | - | Tumor Size Summary | 510 |
| Behavior | 3 |  |
| Stage Data items |
| AJCC Stage |
| Clinical T | 88 | Pathological T | 88 | Post-therapy T | - |
| cT Suffix | - | pT Suffix | - | ypT Suffix | - |
| Clinical N | 88 | Pathological N | 88 | Post-therapy N | - |
| cN Suffix | - | pN Suffix |  | ypN Suffix | - |
| Clinical M | 88 | Pathological M | 88 | Post-therapy M | - |
| Clinical Stage  | 88 | Pathological Stage | 88 | Post-therapy Stage | - |
| SS2018/EOD |
| Summary Stage 2018  | 2 |
| EOD Primary Tumor | 500 | EOD Regional Nodes | 888 | EOD Mets | 00 |
| Regional Nodes Positive | 99 | Regional Nodes Examined | 99 |  |
|  |
| SSDI |
| Brain Molecular Markers | 07 |  |
| Chromosome 1p Status | 1 |
| Chromosome 19q Status | 1 |
| MGMT | 9 |
|  |
| Treatment |
| Surgery Codes |  | **Systemic Therapy Codes** |
| Diagnostic Staging Procedure | 00 | Chemotherapy | 99 |
| Surgical Procedure of Primary Site | 30 | Hormone Therapy | 00 |
| Scope of Regional Lymph Node Surgery | 9 | Immunotherapy | 00 |
| Date of Regional LN Dissection/Flag | 11 |  |  |
| Surgical Procedure/ Other Site | 0 |  |  |

Standard treatment options for anaplastic oligodendrogliomas include Surgery plus radiation with or without chemotherapy. (<https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq#_1144_toc>)